Amita Shukla-Dave

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 109:1315-22. 2012
  2. pmc Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
  3. pmc Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 250:803-12. 2009
  4. ncbi request reprint Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    Radiology 245:499-506. 2007
  5. ncbi request reprint Imaging low-risk prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:78-86. 2008
  6. pmc Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases
    Amita Shukla Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Phys 9:4. 2009
  7. pmc Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles
    Amita Shukla-Dave
    Departments of Medical Physics, Memorial Sloan Kettering Cancer Center New York, New York, USA
    Clin Cancer Res 15:3842-9. 2009
  8. ncbi request reprint Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations
    Amita Shukla-Dave
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 231:717-24. 2004
  9. ncbi request reprint Loss of the tumor suppressor PML in human cancers of multiple histologic origins
    Carmela Gurrieri
    Molecular Biology Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:269-79. 2004
  10. pmc Loss of p63 expression is associated with tumor progression in bladder cancer
    Marshall J Urist
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:1199-206. 2002

Detail Information

Publications128 found, 100 shown here

  1. pmc Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 109:1315-22. 2012
    ..Upon initial testing, the new MR models performed significantly better than a clinical model lacking detailed biopsy data...
  2. pmc Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
    ..The goal of this study was to assess the prognostic value of pretreatment DCE-MRI in head and neck squamous cell carcinoma (HNSCC) patients with nodal disease undergoing chemoradiation therapy or surgery...
  3. pmc Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 250:803-12. 2009
    ....
  4. ncbi request reprint Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    Radiology 245:499-506. 2007
    ....
  5. ncbi request reprint Imaging low-risk prostate cancer
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:78-86. 2008
    ..The review discusses the potential role of imaging in identifying low-risk prostate cancer and enabling more appropriate management of the disease...
  6. pmc Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases
    Amita Shukla Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Phys 9:4. 2009
    ..Further validation of the Avg-AIF approach with a larger population and in multiple regions is desirable...
  7. pmc Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles
    Amita Shukla-Dave
    Departments of Medical Physics, Memorial Sloan Kettering Cancer Center New York, New York, USA
    Clin Cancer Res 15:3842-9. 2009
    ....
  8. ncbi request reprint Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations
    Amita Shukla-Dave
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 231:717-24. 2004
    ..To determine whether chronic prostatitis affects three-dimensional proton magnetic resonance (MR) spectroscopic imaging in evaluation of disease in the peripheral zone...
  9. ncbi request reprint Loss of the tumor suppressor PML in human cancers of multiple histologic origins
    Carmela Gurrieri
    Molecular Biology Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:269-79. 2004
    ..However, its role in the pathogenesis of human cancers other than APL is still unclear. We therefore assessed the status and expression of the PML gene in solid tumors of multiple histologic origins...
  10. pmc Loss of p63 expression is associated with tumor progression in bladder cancer
    Marshall J Urist
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:1199-206. 2002
    ..These data indicate that in contrast to the skin and prostate, p63 is not required for formation of a bladder epithelium but is indispensable for the specific differentiation of a transitional urothelium...
  11. ncbi request reprint p63 expression profiles in human normal and tumor tissues
    Charles J Di Como
    Division of Molecular Pathology, Department of Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 8:494-501. 2002
    ..The p63 gene, located on chromosome 3q27-28, is a member of the p53 gene family. The product encoded by the p63 gene has been reported to be essential for normal development...
  12. pmc Gene discovery in bladder cancer progression using cDNA microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 163:505-16. 2003
    ..The present study has identified molecular biomarkers of potential clinical significance and critical molecular targets associated with bladder cancer progression...
  13. ncbi request reprint p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer
    Pere Puig
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5642-51. 2003
    ..To characterize the expression profile of p73 in human normal tissues by immunohistochemistry (IHC) and to analyze the correlation between p73 expression and bladder cancer progression...
  14. pmc Pten dose dictates cancer progression in the prostate
    Lloyd C Trotman
    Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York, USA
    PLoS Biol 1:E59. 2003
    ..Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression...
  15. pmc The TLX1 oncogene drives aneuploidy in T cell transformation
    Kim De Keersmaecker
    Institute for Cancer Genetics, Columbia University, New York, New York, USA
    Nat Med 16:1321-7. 2010
    ..These results identify a previously unrecognized mechanism contributing to chromosomal missegregation and aneuploidy active at the earliest stages of tumor development in the pathogenesis of cancer...
  16. pmc Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
    ..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment...
  17. ncbi request reprint Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
    Takahiro Maeda
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 433:278-85. 2005
    ..Pokemon's critical role in cellular transformation makes it an attractive target for therapeutic intervention...
  18. pmc An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy
    Kristen L Zakian
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Urol 184:2320-7. 2010
    ..We determined whether pretreatment endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging predicts biochemical recurrence after radical prostatectomy...
  19. ncbi request reprint Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 34:54-64. 2003
    ..The molecular phenotype, p27(+)Bcl-2(+)Ki-67(-)mdm2(+), appears to be unique to nonmalignant parathyroid tumors, and multimarker phenotypes are more complex in carcinomas...
  20. ncbi request reprint Expression of p63 in diffuse large B-cell lymphoma
    Cyrus V Hedvat
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:237-42. 2005
    ..Even though in univariate analysis p63 expression did not correlate with overall survival, the association of p63 with increased proliferative index suggests its involvement in DLBCL tumor progression...
  21. ncbi request reprint PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
    Rosa Bernardi
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 442:779-85. 2006
    ..Thus, our findings identify PML as a novel suppressor of mTOR and neoangiogenesis...
  22. ncbi request reprint Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6973-80. 2002
    ..However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms...
  23. ncbi request reprint Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control
    Eva Hernando
    Department of Pathology, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Nature 430:797-802. 2004
    ....
  24. doi request reprint Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth
    Barry H Smith
    The Rogosin Institute, New York, New York 10021, USA
    Cancer Res 71:725-35. 2011
    ....
  25. ncbi request reprint Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3841-9. 2002
    ..This study evaluates such molecular phenotypes with regard to cell cycle regulation and proliferation and determines their significance for patient outcome...
  26. ncbi request reprint The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
    Eva Hernando
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Med 13:748-53. 2007
    ....
  27. ncbi request reprint HDM2 protein overexpression and prognosis in primary malignant melanoma
    David Polsky
    Department of Dermatology, Medical Center, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA
    J Natl Cancer Inst 94:1803-6. 2002
    ..33 to 0.94; two-sided chi(2) P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation...
  28. pmc Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression
    Orit Karni-Schmidt
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Am J Pathol 178:1350-60. 2011
    ..This study highlights the relevance of p63 isoforms in both urothelial development and bladder carcinoma progression, with ΔNp63 acting as an oncogene in certain invasive bladder tumors...
  29. ncbi request reprint Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia
    Carmela Gurrieri
    Molecular Biology Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, Sloan Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Blood 103:2358-62. 2004
    ..Complete functional loss of PML is therefore selected by the APL phenotype and associates with poor prognosis and RA unresponsiveness...
  30. ncbi request reprint Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results
    Kristen L Zakian
    Departments of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 229:241-7. 2003
    ..To determine whether cancers of the prostate transition zone (TZ) possess a unique metabolic pattern by which they may be identified at proton magnetic resonance (MR) spectroscopic imaging...
  31. pmc Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI
    Michael H Fuchsjäger
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 78:743-50. 2010
    ..To investigate whether pretreatment endorectal magnetic resonance imaging (MRI) findings can predict biochemical relapse in patients with clinically localized prostate cancer treated with external beam radiation therapy (EBRT)...
  32. pmc Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 162:609-17. 2003
    ..A potential tumor suppressor role in bladder cancer was revealed for KiSS-1. Moreover, it showed predictive value by identifying patients with poor outcome...
  33. pmc Ubiquitination regulates PTEN nuclear import and tumor suppression
    Lloyd C Trotman
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 128:141-56. 2007
    ....
  34. pmc Identification of a tumour suppressor network opposing nuclear Akt function
    Lloyd C Trotman
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 441:523-7. 2006
    ..Our results demonstrate that Pml orchestrates a nuclear tumour suppressor network for inactivation of nuclear pAkt, and thus highlight the importance of AKT compartmentalization in human cancer pathogenesis and treatment...
  35. ncbi request reprint A multigenic program mediating breast cancer metastasis to bone
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Cell 3:537-49. 2003
    ....
  36. doi request reprint Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease
    Michael J Donovan
    Aureon Laboratories, Yonkers, New York, NY, USA
    BJU Int 105:462-7. 2010
    ....
  37. doi request reprint Personalized prediction of tumor response and cancer progression on prostate needle biopsy
    Michael J Donovan
    Aureon Laboratories, Inc, New York, New York 10701, USA
    J Urol 182:125-32. 2009
    ..We developed a patient specific, biology driven tool to predict outcome at diagnosis. We also investigated whether biopsy androgen receptor levels predict a durable response to therapy after secondary treatment...
  38. pmc ETS rearrangements and prostate cancer initiation
    Brett S Carver
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 457:E1; discussion E2-3. 2009
    ..To this end, we demonstrate that the prostate-specific overexpression of ERG does not initiate prostate tumorigenesis...
  39. pmc Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
    Zhenbang Chen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 436:725-30. 2005
    ..Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours...
  40. doi request reprint Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings
    Yousef Mazaheri
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278, New York, NY 10021, USA
    Radiology 246:480-8. 2008
    ....
  41. ncbi request reprint Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy
    Kristen L Zakian
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 234:804-14. 2005
    ..To determine whether hydrogen 1 magnetic resonance (MR) spectroscopic imaging can be used to predict aggressiveness of prostate cancer...
  42. ncbi request reprint Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder
    Jin Cheng
    Department of Urology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, USA
    Cancer Res 63:179-85. 2003
    ..On the basis of our current and previous transgenic studies, we have proposed an integrated pathway progression model of bladder cancer...
  43. pmc Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression
    Li Ma
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 19:1779-86. 2005
    ....
  44. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  45. pmc Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway
    Igor Matushansky
    Department of Medicine, Columbia University, New York, New York 10032, USA
    J Clin Invest 117:3248-57. 2007
    ..Our results provide mechanistic insights regarding the cell of origin of MFH, establish what we believe is a novel tumor suppressor role for Wnt signaling, and identify a potential therapeutic differentiation strategy for sarcomas...
  46. pmc Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited
    Monica Garcia-Barros
    Laboratory of Signal Transduction and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center Department of Pathology, Columbia University, New York, NY 10065, USA
    Cancer Res 70:8179-86. 2010
    ....
  47. ncbi request reprint Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  48. ncbi request reprint Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin
    Eiji Kikuchi
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1835-42. 2004
    ..The purpose of this study was to investigate whether local overexpression of endostatin could serve to diminish tumor growth of bladder cancer in vivo...
  49. ncbi request reprint Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients
    Marija Drobnjak
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 9:2613-9. 2003
    ..The abundance of p27, an inhibitor of cell proliferation, is controlled by Skp2-dependent proteolysis...
  50. pmc Comparing primary tumors and metastatic nodes in head and neck cancer using intravoxel incoherent motion imaging: a preliminary experience
    Yonggang Lu
    From the Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY Department of Radiology, Maastricht University Medical Center, Maastricht, The Netherlands Department of Radiology, Department of Radiation Oncology, Department of Biostatistics, Department of Pathology, and Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
    J Comput Assist Tomogr 37:346-52. 2013
    ..This study aimed to use intravoxel incoherent motion (IVIM) imaging for investigating differences between primary head and neck tumors and nodal metastases and to evaluate IVIM efficacy in predicting outcome...
  51. ncbi request reprint The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 99:786-93. 2007
    ..To design new models that combine clinical variables and biopsy data with magnetic resonance imaging (MRI) and MR spectroscopic imaging (MRSI) data, and assess their value in predicting the probability of insignificant prostate cancer...
  52. ncbi request reprint A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
    ..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
  53. ncbi request reprint Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
    Mithat Gonen
    Departments of Epidemiology and Biostatistics, Medicine, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:406-12. 2003
    ....
  54. pmc Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study
    Hebert Alberto Vargas
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278, New York, NY 10065, USA
    Radiology 265:478-87. 2012
    ....
  55. pmc Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging
    Jingbo Zhang
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278, New York, NY 10065, USA
    Radiology 253:425-34. 2009
    ....
  56. pmc A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas
    Igor Matushansky
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
    Am J Pathol 172:1069-80. 2008
    ..Our results indicate that a degree of developmental maturity can be quantitatively assigned to solid tumors, supporting the notion that transformation of a solid tumor stem cell can occur at distinct stages of maturation...
  57. ncbi request reprint Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer
    Li Ma
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 67:7106-12. 2007
    ..Importantly, our results indicate that Erk-mediated phosphorylation and inactivation of TSC2 can be critical in development of hamartomatous lesions in TSC and cancer pathogenesis...
  58. ncbi request reprint p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development
    Carmen Carneiro
    Department of Molecular Biology, Menmorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 22:361-9. 2003
    ..From these studies, we concluded that the absence of p27 disabled the trigger for an Arf-dependent apoptotic response in Rb-/- tumor cells. This suggests a novel mechanism by which the loss of p27 may impact on tumor development...
  59. pmc Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
    Hui Kuan Lin
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nature 464:374-9. 2010
    ..Our findings therefore provide proof-of-principle evidence that pharmacological inhibition of Skp2 may represent a general approach for cancer prevention and therapy...
  60. pmc Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1)
    Yuhui Liu
    Department of Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    EMBO J 26:4683-93. 2007
    ..These genetic results suggest that p21 acts through the cyclin D1-cdk4 complex to support tumor growth, and establish the utility of using a somatic cell modeling system for defining the contribution proteins make to tumor development...
  61. pmc Role of Dok-1 and Dok-2 in leukemia suppression
    Masaru Niki
    Cancer Biology and Genetics Program and Dept of Pathology, Box 110, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:1689-95. 2004
    ..These findings unravel the critical and unexpected role of Dok-1 and Dok-2 in tumor suppression and control of the hematopoietic compartment homeostasis...
  62. ncbi request reprint Oncogenes in melanoma
    David Polsky
    Department of Dermatology, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA
    Oncogene 22:3087-91. 2003
    ..We provide a general overview of the mechanisms of oncogene activation and the functions of oncogenes. Lastly, we review oncogenic events in melanoma...
  63. ncbi request reprint Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:3296-302. 2005
    ..The clinical evaluation of Drg1 in colorectal cancer has been limited. We performed this study to evaluate the role of Drg1 in a large cohort of patients with metastatic colorectal cancer who were irinotecan naive...
  64. ncbi request reprint p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition
    Susana Gonzalez
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Res 65:2186-92. 2005
    ..In the clinical context, these results might have potential therapeutic implications, because p73beta could induce alternative apoptotic responses in tumors harboring p53 mutations...
  65. pmc Extension of the intravoxel incoherent motion model to non-gaussian diffusion in head and neck cancer
    Yonggang Lu
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Magn Reson Imaging 36:1088-96. 2012
    ..To extend the intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI) model to restricted diffusion and to simultaneously quantify the perfusion and restricted diffusion parameters in neck nodal metastases...
  66. ncbi request reprint Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence
    Darko Pucar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 69:62-9. 2007
    ....
  67. pmc The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience
    Cecilia Wassberg
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    AJR Am J Roentgenol 199:360-6. 2012
    ....
  68. pmc Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1403-10. 2010
    ....
  69. ncbi request reprint Racial disparity of epidermal growth factor receptor expression in prostate cancer
    Brian Shuch
    Department of Urology, New York University Cancer Institute, New York, NY, USA
    J Clin Oncol 22:4725-9. 2004
    ..This has therapeutic relevance because a better understanding of the molecular basis underlying the ethnic variability will help in the design of individualized treatment regimens using EGFR inhibitors...
  70. doi request reprint Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa
    Jimmy A Rotolo
    Laboratory of Signal Transduction, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 70:804-15. 2008
    ..To address in vivo the issue of whether Bax and Bak are functionally redundant in signaling apoptosis, capable of substituting for each other...
  71. pmc Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
    Teresa Palomero
    Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA
    Nat Med 13:1203-10. 2007
    ....
  72. pmc NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN
    Xinjiang Wang
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 522, New York, NY 10021, USA
    Cell 128:129-39. 2007
    ..Therefore, NEDD4-1 is a potential proto-oncogene that negatively regulates PTEN via ubiquitination, a paradigm analogous to that of Mdm2 and p53...
  73. ncbi request reprint Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification
    Davide Ruggero
    Molecular Biology Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Science 299:259-62. 2003
    ..These results suggest that deregulated ribosome function is important in the initiation of DC, whereas telomere shortening may modify and/or exacerbate DC...
  74. pmc Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, The Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:365-71. 2002
    ..6; 95% confidence interval = 1.9 to 29.6). The findings suggest that the 3q copy number status is an important marker for tumor progression and prognostication in patients with head and neck squamous cell carcinoma...
  75. doi request reprint Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer
    Hebert Alberto Vargas
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Electronic address
    J Urol 188:1732-8. 2012
    ..We assessed the value of endorectal magnetic resonance imaging in predicting upgrading on confirmatory biopsy in men with low risk prostate cancer...
  76. pmc Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oral Oncol 48:717-22. 2012
    ..Future studies with larger patient populations need to be carried out to validate and clarify our preliminary findings...
  77. pmc Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume
    Yousef Mazaheri
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278, New York, NY 10065, USA
    Radiology 252:449-57. 2009
    ....
  78. pmc Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience
    Darko Pucar
    Department of Radiology, Medical Physics, Epidemiology and Biostatistics, Urology, Pathology, and Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 236:545-53. 2005
    ..To prospectively evaluate magnetic resonance (MR) imaging and MR spectroscopy for depiction of local prostate cancer recurrence after external-beam radiation therapy, with step-section pathologic findings as the standard of reference...
  79. pmc Inactivation of p53 and Pten promotes invasive bladder cancer
    Anna M Puzio-Kuter
    Department of Urology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    Genes Dev 23:675-80. 2009
    ..Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease...
  80. pmc Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis
    Lan Mo
    Department of Urology, New York University Cancer Institute, New York University School of Medicine, New York, New York, USA
    J Clin Invest 117:314-25. 2007
    ....
  81. ncbi request reprint Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes
    Marta Sanchez-Carbayo
    Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, York, New York 10021, USA
    Lab Invest 83:507-17. 2003
    ..This study further elucidates the genetic events associated with MDR1 expression and identifies novel targets associated with multidrug resistance...
  82. ncbi request reprint Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology and Computational Biology Center Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:778-89. 2006
    ..Bladder cancer is a common malignancy characterized by a poor clinical outcome when tumors progress into invasive disease. We sought to define genetic signatures characteristic of aggressive clinical behavior in advanced bladder tumors...
  83. ncbi request reprint Adrenocortical carcinoma: clinical, morphologic, and molecular characterization
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:941-50. 2002
    ..To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters...
  84. pmc Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study
    Jing Qi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    NMR Biomed 26:204-12. 2013
    ..Six of 26 patients developed steatosis during chemotherapy. Lipid changes were observable at 6 weeks...
  85. doi request reprint Diffusion-weighted magnetic resonance imaging of the prostate: improved robustness with stretched exponential modeling
    Yousef Mazaheri
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Comput Assist Tomogr 36:695-703. 2012
    ..This study aimed to compare the intraclass correlation coefficients of parameters estimated with stretched exponential and biexponential diffusion models of in vivo diffusion-weighted magnetic resonance imaging (MRI) of the prostate...
  86. doi request reprint MRI of the prostate: clinical relevance and emerging applications
    Yousef Mazaheri
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    J Magn Reson Imaging 33:258-74. 2011
    ....
  87. ncbi request reprint 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization
    Kristen L Zakian
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, NY, USA
    Cancer Biomark 4:263-76. 2008
    ..This article reviews the assessment of choline-containing compounds, citrate, and polyamines as markers for prostate tumor detection and aggressiveness...
  88. doi request reprint Motion correction of multi-b-value diffusion-weighted imaging in the liver
    Yousef Mazaheri
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Acad Radiol 19:1573-80. 2012
    ..The objective of this article is to present a reliable method to reduce motion-related artifacts during free-breathing at higher b-values when signal levels are low...
  89. doi request reprint Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy
    Michael H Fuchsjäger
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 104:315-20. 2009
    ..To investigate whether magnetic resonance imaging (MRI) findings, when converted into a scoring system, can predict the biochemical recurrence of prostate cancer after radical prostatectomy (RP)...
  90. ncbi request reprint Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy
    Kristen L Zakian
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 63:9042-7. 2003
    ..The results are promising, although a prospective study is necessary for confirmation. (31)P MRSI appears to be a useful tool for the prediction of survival before therapy in bone sarcomas...
  91. ncbi request reprint Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent
    Iman Osman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2980-7. 2002
    ..To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent...
  92. ncbi request reprint The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer
    Michael Fuchsjager
    Department of Radiology, Medical University of Vienna, Vienna, Austria, and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 7:193-202. 2009
    ..This review will provide a brief overview of MRI techniques relevant to prostate cancer, including MR spectroscopic imaging, and discuss the ways that they can aid in diagnosis, treatment selection, and post-treatment follow-up...
  93. doi request reprint MR imaging of the prostate in clinical practice
    Yousef Mazaheri
    Departments of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    MAGMA 21:379-92. 2008
    ..This review summarizes the role of MR imaging in the management of prostate cancer and describes practical approaches to implementing anatomic, metabolic and functional MR imaging techniques in the clinic...
  94. pmc Improved prediction of prostate cancer recurrence through systems pathology
    Carlos Cordon-Cardo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Invest 117:1876-83. 2007
    ..This robust platform has broad applications in patient diagnosis, treatment management, and prognostication...
  95. ncbi request reprint Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods
    Ming Lan Lu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:171-9. 2002
    ..015), and it appears to be a significant prognostic factor associated with patient survival...
  96. pmc 31P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization
    Jing Qi
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Magn Reson Imaging 34:336-44. 2011
    ..Second, to compare the biophysiologic differences between hepatic regeneration stimulated by PVE and by partial hepatectomy (PH)...
  97. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  98. ncbi request reprint Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma
    José M García-Castellano
    Orthopaedic Surgery Service, affiliated with Weil Medical College of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 8:782-7. 2002
    ..The aim of this study was to investigate the frequency of molecular alterations in MTAP in osteosarcoma...
  99. ncbi request reprint Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Oncogene 22:5298-305. 2003
    ..Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer...
  100. ncbi request reprint A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 11:3836-45. 2005
    ..We initiated a phase I trial of the sequential combination of irinotecan followed by flavopiridol to determine the maximal tolerated dose of this combination therapy...
  101. ncbi request reprint p27 as a target for cancer therapeutics
    Stacy W Blain
    Department of Cell Biology and Genetics, Memorial Sloan Kettering Cancer Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 3:111-5. 2003

Research Grants5

  1. MR Dynamic Imaging and Spectroscopy in Head & Neck Cancers
    AMITA DAVE; Fiscal Year: 2007
    ..If successful, it will provide an a priori predictor of failure/response to chemotherapy and/or long term disease free-survival, resulting in patient specific treatment which will likely enhance outcome. ..
  2. MR Dynamic Imaging and Spectroscopy in Head & Neck Cancers
    AMITA DAVE; Fiscal Year: 2010
    ..If successful, it will provide an a priori predictor of failure/response to chemotherapy and/or long term disease free-survival, resulting in patient specific treatment which will likely enhance outcome. ..